MCET (MultiCell Technologies) Cyclically Adjusted Revenue per Share: $0.00 (As of Aug. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MultiCell Technologies Cyclically Adjusted Revenue per Share?

MultiCell Technologies MCET -90.00% Cyclically Adjusted Revenue per Share is $0.00 as of Aug. 2015.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MultiCell Technologies's adjusted revenue per share for the three months ended in Aug. 2015 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Aug. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-06), MultiCell Technologies's current stock price is $1.0E-5. MultiCell Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2015 was $0.00. MultiCell Technologies's Cyclically Adjusted PS Ratio of today is .


MultiCell Technologies  (OTCPK:MCET) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MultiCell Technologies Cyclically Adjusted Revenue per Share Related Terms


MultiCell Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Cyclically Adjusted Revenue per Share Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MCET vs ERGO, OPLI, GLAG: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, MultiCell Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MultiCell Technologies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Cyclically Adjusted PS Ratio falls into.



MultiCell Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MultiCell Technologies's adjusted Revenue per Share data for the three months ended in Aug. 2015 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Aug. 2015 (Change)*Current CPI (Aug. 2015)
=0/238.3160*238.3160
=0.000

Current CPI (Aug. 2015) = 238.3160.

MultiCell Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200511 0.002 197.600 0.002
200602 0.017 198.700 0.020
200605 0.001 202.500 0.001
200608 0.001 203.900 0.001
200611 0.002 201.500 0.002
200702 0.001 203.499 0.001
200705 0.001 207.949 0.001
200708 0.001 207.917 0.001
200711 0.002 210.177 0.002
200802 0.001 211.693 0.001
200805 0.001 216.632 0.001
200808 0.001 219.086 0.001
200811 0.001 212.425 0.001
200902 0.000 212.193 0.000
200905 0.000 213.856 0.000
200908 0.000 215.834 0.000
200911 0.000 216.330 0.000
201002 0.000 216.741 0.000
201005 0.000 218.178 0.000
201008 0.000 218.312 0.000
201011 0.000 218.803 0.000
201102 0.000 221.309 0.000
201105 0.000 225.964 0.000
201108 0.000 226.545 0.000
201111 0.000 226.230 0.000
201202 0.000 227.663 0.000
201205 0.000 229.815 0.000
201208 0.000 230.379 0.000
201211 0.000 230.221 0.000
201302 0.000 232.166 0.000
201305 0.000 232.945 0.000
201308 0.000 233.877 0.000
201311 0.000 233.069 0.000
201402 0.000 234.781 0.000
201405 0.000 237.900 0.000
201408 0.000 237.852 0.000
201411 0.000 236.151 0.000
201502 0.000 234.722 0.000
201505 0.000 237.805 0.000
201508 0.000 238.316 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
MultiCell Technologies (MCET) has a Cyclically Adjusted Revenue per Share of $0.00 as of Aug. 2015. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Cyclically Adjusted Revenue per Share too high?
MultiCell Technologies' current Cyclically Adjusted Revenue per Share is $0.00.
How does MultiCell Technologies' Cyclically Adjusted Revenue per Share compare to ERGO and OPLI?
MultiCell Technologies' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Cyclically Adjusted Revenue per Share is $0.00 as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.